The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors
- 1 September 2009
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (9), 2496-2508
- https://doi.org/10.1158/1535-7163.mct-09-0302
Abstract
Angiogenesis is crucial for development and metastasis of tumors, and vascular endothelial growth factor (VEGF) is a key mediator of this process. The importance of VEGF in tumorigenesis and tumor progression makes it an attractive target for the development of anticancer therapies. Inhibition of angiogenesis has shown promising clinical efficacy; however, not all patients treated with antiangiogenic agents derive benefit from them. Some patients are predisposed to refractory disease, whereas others develop resistance after initial response. Patients may also have different severity of drug-related adverse events. Optimization of drug administration based on disease status and individual responsiveness is important in limiting the treatment failure and minimization of side-effects. Single nucleotide polymorphisms (SNP) in VEGF may alter VEGF protein concentrations, influence the process of angiogenesis, and may relate to interindividual variation in the risk and progression of selected tumors, and their resistance to treatments. This review examines the role of SNPs in the VEGF gene as predictive and prognostic markers for major solid tumors, including the breast, non-small cell lung, colorectal, and prostate cancers. Selected VEGF SNPs seem to be associated with risk of these cancers; however, there is lack of unanimity in findings, in part influenced by differences in study design and analysis. [Mol Cancer Ther 2009;8(9):2496–508]Keywords
Other Versions
This publication has 72 references indexed in Scilit:
- Genomewide Association Studies and Human DiseaseThe New England Journal of Medicine, 2009
- Breast cancer susceptibility: current knowledge and implications for genetic counsellingEuropean Journal of Human Genetics, 2008
- Common 5p15.33 and 6p21.33 variants influence lung cancer riskNature Genetics, 2008
- Genome-wide association studies in cancerHuman Molecular Genetics, 2008
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100Journal of Clinical Oncology, 2008
- Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancerAnnals of Oncology, 2008
- Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1Nature Genetics, 2008
- The promise and limitations of genome-wide association studies to elucidate the causes of breast cancerBreast Cancer Research, 2007
- Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literatureBritish Journal of Cancer, 2006
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986